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Purpose 
Although studies rjtained during the 1970s suggested that 
simple radionuclide scintirenography offered levels of scnsi- 
tivity and specificity not different from those of intravenous 
urography, recent reports indicate that the addition of au 
angiotensin-converting enzyme (ACE) inhibitor magnifies 
the difference in function between the kidneys in the pres- 
ence of functionally significant vascular stenosis. In several 
series of patients undergoing arteriography, ACE inhibitor 
scintirenography provides a very high degree of sensitivity. 
The predictive accuracy of radionuclide scintirenography 
may be enhanced by selecting hypertensive patients with a 
higher likelihood of the disease, e.g., young patients, espe- 
cially female, with a bruit over the kidneys (likely IO have 
fibromuscular dysplasia); patients with an acceleration of 
previously easily controlled hypertension: patients with 
other evidence of occlusive atherosclerotic disease, heavy 
tobacco use or resistant hypertension: patients with estah- 
lished hypertension and an otherwise unexplained decline in 
renal function; patients with conlinuous bruits over Ihe 
kidneys: patients found to have irregularly shaped or small 
kidneys (especially unilateral), and new or more severe renal 
failure while receiving au ACE inhibitor. Radionudide scin- 
tirenography also may be empioyed when known renovas- 
cular disease is treated medically and after renal revascular- 
ization procedures to ascertain sequential changes in 
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symmetry of perfusion attributable to vascular stenosis and 
localized abnormalities such as small vessel infarction. 
ACE Inhibitor Scintirenography 
Radionuclide study of the renovascular bed combined 
with the physiologic challenge of ACE inhibition (e.g., by 
oral captopril or intravenous enalaprilat) is a useful test in 
the evaluation of the patient in whom the diagnosis of 
renovascular hypertension is being considered. Shorf-term 
ACE inhibition acts as a pharmacologic probe to evaluate 
the patient’s renin-angiotensin-aldosterone system. In brief, 
when renal perfusion pressure is reduced (as in states of 
preglomerular stenosis), the transcapillary forces driving 
glomerular MtraIion are maintained by an angiotensin-ll- 
dependent vasoconstridion of the efferent arteriole. When 
rhis angiotensin-U-dependent vasoconstrictiou is removed 
afIer therapy with ACE inhibition. glomerular filtration (and 
urinary flow) of the kidney distal IO the stenosis decreases. 
This reduction in ipsilateral renal function can be assessed 
noninvasively with radionuclide scintirenography. 
To perform the study, most commonly captoprll (25 or 
50 ma*) is given orally I h before wrformance of conven- 
tionairadioiuclide s&dies, Angiotknsin-converting enzyme 
inhibitors are bes! withheld for 2 to 5 days before the test to 
reduce the possibility of a false negarive result that may be 
seen with long-term ACE inhibition. Intravenous enalaprilat 
in place of or4 captoprll has also been used in some centers 
because of a more rapid onset of action. In some studies, 
furosemide has been given along with the captopril to reduce 
false positive test results due to pelvic retention of radionu- 
elide. Administration ofother antihypertensive drugs may be 
continued. The patient should be adequately hydrated, par- 
ticularly if diuretics are being administered, and the blood 
pressure should be monitored frequently. If desired, plasma 
renin may be sampled before and after captopril administra- 
tion to complete a captopril-plasma renin activity test in 
addition IO scintirenography. 
‘No data are .wailaMe to support the choice of dosage. 
Technique 
Current radionuclide scintireuograpby prnvides sequen- 
tial images of the distribution of radioactivity in the kidney 
during a period of at least 7.0 and preferably 30 min and the 
generation of time-activity cures over each kidney to dem- 
onstrate in a scmiquarditative manner Ihe relative u,!ake 
and excretion of the radionuclide. The two modalities are 
evaluated in acomplementary fashion. The radiopharmaceu- 
ticals most commonly available for prrfarmance of renal 
radionuclide studies include technetium%m DTPA (excret- 
ed by glomerular filtration). hipfwan l-131 (excreted by 
combined tubular secretion and glomerular tiitrationl. and 
technetium-99m metcaptosuccinylglycylglycylglycine 
(MAG3) (excreted almost solely by tubular secretion). Cur- 
rently available data do not support a distinction beween 
technetium-99m DTPA and technetium-99m MAG3 in terms 
of relative sensitivity and specificity. Regardless of which 
agent is used, the irnerpretation of the study is similar. 
Interpretation 
renogram after captopril administration makes the presence 
of hemodynamicly sign&ant renal artery stew& unlikely. 
When the scintirenogmm is abnormal and unchanged 
after short-term administration of an ACE inhibitor-that is, 
there is a fixed abnormality-parewhymrd disease is most 
likely. However. in the presence of azotemia (creatinine 
a2 0 mg/dl). severe unilateral renal artery stenosis or bilat- 
eral renal artery stenosis, a lack of change after edministra- 
tion of an ACE inhibitor may not rule out hemodynamically 
important renal artery stenases (although the scintirenogram 
is almost always abnormal). 
Ahhough rhe change in the scintkenogram after adminis- 
tration of an ACE inhibitor is the most diagnostic indicator 
of renal artery stenosis. many centers perform the 4CE 
inhibitor-stimulate0 scintircnography without first obtaining 
a baseline siudy. If the ACE inhibitor-stimulated radionla- 
clidc study is abnormal, a subsequent baseline study without 
an ACE inhibiror should be otnained for comparative pur. 
poses. Alternatively. the clinician may wish IO forgo the 
baseline renogram and proceed directly to renal angiogmphy 
if the clinicaf index of suspicion of renovascular hypcrten- 
sion is high. 
Images should be obtained at 2- to 3-min intervals and are 
evaluated for relative uptake, size and shape of the kidney 
and the presence or absence of abnormalities iz transit from 
the renal cortex to the renal pelvis and bladder. Interpreta- 
tion of the images facilitates the detection of parenchymal 
renal disease and delays in transport from the renal pelvis 
which, particularly when associated with the administration 
of captopril, may Lad to false positive interpretations (see 
later). Evaluation of the images is performed qualitatively. 
The msior variables evaluated from the time-activity 
Conclusions 
Angiotensin-converting enzyme inhibitor radionuclide 
scintirenography provides a sensitive, noninvasive examine- 
lion for hemodynrunically important renovascular disease. I1 
should not be applied as a universal screening test but can 
reasonably exclude ordirecl further studies in p&emgroups 
at high risk for renovascdlar disease. 
cwves are-the uptake of each kidney at =;I to 2 min ii 
renal aelvis must be excluded. Althouah immediatelv after 
relation to total renal uptake: time to reach the peak activity, 
and the amount of activity remaining in the kidney al 20 or 
30 min in relation to the peak activity. Abnormalities sug- 
gestive of renovascular hypertension are a decrease in the 
relative uptake (the normal difference is 45% to 55%). a 
prolongation of the time to reach peak activity (the normal 
value is ~3 to 6 min) and an increased ratio of rhe activity at 
20 or 30 min to the peak activity (the normal value depends 
on the specific technique use? and should be determined for 
each institution). Qualitative changes suggestive of renovas- 
cular hypertension after adminis&ation of an ACE inhibitor 
are a change in the time-activity curve-that is. a decreased 
rate of uptake of isotope by the kidney. a lower and 
prolonged peak activity and a slower washout from the 
kidney. In evaluating the slower washout, retention in the 
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